EE03594B1 - Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine - Google Patents

Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine

Info

Publication number
EE03594B1
EE03594B1 EE9800136A EE9800136A EE03594B1 EE 03594 B1 EE03594 B1 EE 03594B1 EE 9800136 A EE9800136 A EE 9800136A EE 9800136 A EE9800136 A EE 9800136A EE 03594 B1 EE03594 B1 EE 03594B1
Authority
EE
Estonia
Prior art keywords
preparation
pharmaceutical composition
composition suitable
depot administration
depot
Prior art date
Application number
EE9800136A
Other languages
English (en)
Estonian (et)
Other versions
EE9800136A (et
Inventor
Karel Jozef Fran�ois Marc
Carolus Augusta Embrechts Roger
Karel Borghijs Herman
Monbaliu Johan
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03594(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE9800136A publication Critical patent/EE9800136A/xx
Publication of EE03594B1 publication Critical patent/EE03594B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EE9800136A 1996-05-20 1997-05-12 Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine EE03594B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20
PCT/EP1997/002504 WO1997044039A1 (en) 1996-05-20 1997-05-12 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Publications (2)

Publication Number Publication Date
EE9800136A EE9800136A (et) 1998-10-15
EE03594B1 true EE03594B1 (et) 2002-02-15

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800136A EE03594B1 (et) 1996-05-20 1997-05-12 Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine

Country Status (38)

Country Link
US (1) US6077843A (pl)
EP (1) EP0904081B1 (pl)
JP (1) JP3274687B2 (pl)
KR (1) KR100358373B1 (pl)
CN (1) CN1093762C (pl)
AR (1) AR007194A1 (pl)
AT (1) ATE208619T1 (pl)
AU (1) AU715572B2 (pl)
BG (1) BG62684B1 (pl)
BR (1) BR9706824B8 (pl)
CA (1) CA2236691C (pl)
CY (2) CY2270B1 (pl)
CZ (1) CZ291284B6 (pl)
DE (2) DE69708284T2 (pl)
DK (1) DK0904081T3 (pl)
EA (1) EA000536B1 (pl)
EE (1) EE03594B1 (pl)
ES (1) ES2167745T3 (pl)
FR (1) FR11C0035I2 (pl)
HK (1) HK1017852A1 (pl)
HR (1) HRP970276B1 (pl)
HU (2) HU224025B1 (pl)
ID (1) ID16927A (pl)
IL (1) IL124551A (pl)
LU (1) LU91842I2 (pl)
MX (1) MX9804816A (pl)
MY (1) MY126302A (pl)
NO (2) NO315931B1 (pl)
NZ (1) NZ330369A (pl)
PL (1) PL188309B1 (pl)
PT (1) PT904081E (pl)
SI (1) SI0904081T1 (pl)
SK (1) SK284013B6 (pl)
TR (1) TR199800923T2 (pl)
TW (1) TW487572B (pl)
UA (1) UA61898C2 (pl)
WO (1) WO1997044039A1 (pl)
ZA (1) ZA974331B (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CA2321924A1 (en) * 1998-02-25 1999-09-02 Abbott Laboratories Butorphanol sustained release formulations
AU5489299A (en) * 1998-08-18 2000-03-14 Sepracor, Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
BR0009437A (pt) 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
ATE401313T1 (de) * 2000-08-14 2008-08-15 Teva Pharma Herstellung von risperidon
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
JP4500679B2 (ja) * 2002-07-29 2010-07-14 アルザ・コーポレーシヨン パリペリドンを制御送達する方法および投薬形態物
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
JP4836797B2 (ja) 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
WO2005070332A1 (en) * 2004-01-12 2005-08-04 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP5249748B2 (ja) 2005-04-25 2013-07-31 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
CN101641353B (zh) * 2007-04-19 2012-05-23 长春健欣生物医药科技开发有限公司 用于治疗精神疾病的新颖化合物及其制备方法和用途
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
BRPI0821408A2 (pt) 2007-12-19 2015-06-16 Janssen Pharmaceutica Nv Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação
US20090209757A1 (en) * 2008-01-10 2009-08-20 Santiago Ini Processes for the preparation and purification of paliperidone palmitate
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP3685837A1 (en) 2008-09-04 2020-07-29 Amylin Pharmaceuticals, LLC Sustained release formulations using non-aqueous carriers
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
EP2493473A1 (en) 2009-10-30 2012-09-05 Janssen Pharmaceutica NV Dosing regimen associated with long-acting injectable paliperidone esters
WO2011074017A1 (en) * 2009-12-17 2011-06-23 Alkem Laboratories Ltd. A novel process for the preparation of paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
CN107595771A (zh) 2010-10-18 2018-01-19 大日本住友制药株式会社 注射用缓释制剂
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
ES2587527T3 (es) 2011-05-31 2016-10-25 RAMAMOHAN RAO, Davuluri Preparación de 3-[2-[4-((6-fluoro-1,2-bencisoxazol-3-il)-l-piperidinil)-6,7,8,9-tetrahidro-9-hidroxi-2-metil-4H-pirido[1,2 a]-primidin-4-ona (paliperidona) y palmitato de paliperidona
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
HUE049485T2 (hu) 2015-04-07 2020-09-28 Janssen Pharmaceuticals Inc Adagolási rend hosszan ható, injektálható paliperidon-észterek beadásának elmaradása esetén
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
KR20230116008A (ko) 2020-11-30 2023-08-03 얀센 파마슈티카 엔.브이. 팔리페리돈 팔미테이트 제형의 재현탁을 보장하는 방법
HRP20240074T1 (hr) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem
AU2021389587A1 (en) 2020-11-30 2023-07-13 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
SI4025187T1 (sl) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
WO2023021008A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
SK282231B6 (sk) * 1993-11-19 2001-12-03 Janssen Pharmaceutica N. V. Farmaceutický prostriedok na liečenie psychotických porúch
WO1995013799A1 (en) * 1993-11-19 1995-05-26 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
MX9709451A (es) * 1995-06-06 1998-02-28 Hoechst Marion Roussel Inc Derivados de benzisoxazol e indazol como agentes antipsicoticos.
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
EA000536B1 (ru) 1999-10-28
JP3274687B2 (ja) 2002-04-15
WO1997044039A1 (en) 1997-11-27
BR9706824B8 (pt) 2015-02-18
TR199800923T2 (xx) 1999-09-21
CA2236691A1 (en) 1997-11-27
NO2011015I1 (no) 2011-09-19
AU715572B2 (en) 2000-02-03
UA61898C2 (en) 2003-12-15
JP2000513718A (ja) 2000-10-17
HUS1100013I1 (hu) 2017-03-28
DE69708284D1 (de) 2001-12-20
PL188309B1 (pl) 2005-01-31
HK1017852A1 (en) 1999-12-03
CZ291284B6 (cs) 2003-01-15
NZ330369A (en) 2000-04-28
NO315931B1 (no) 2003-11-17
KR19990067603A (ko) 1999-08-25
BR9706824A (pt) 1999-03-23
AR007194A1 (es) 1999-10-13
US6077843A (en) 2000-06-20
KR100358373B1 (ko) 2003-02-11
MY126302A (en) 2006-09-29
FR11C0035I1 (pl) 2011-07-10
IL124551A0 (en) 1998-12-06
LU91842I2 (fr) 2011-09-20
ZA974331B (en) 1998-11-19
NO981984L (no) 1998-11-19
EP0904081B1 (en) 2001-11-14
HUP9901319A3 (en) 1999-11-29
DK0904081T3 (da) 2002-02-25
ATE208619T1 (de) 2001-11-15
AU2955997A (en) 1997-12-09
EA199800531A1 (ru) 1998-12-24
HRP970276A2 (en) 1998-04-30
EE9800136A (et) 1998-10-15
CY2270B1 (en) 2003-07-04
HUP9901319A2 (hu) 1999-08-30
NO2011015I2 (no) 2013-03-11
SK284013B6 (sk) 2004-08-03
DE69708284T2 (de) 2002-07-25
SK62098A3 (en) 2000-04-10
BG62684B1 (bg) 2000-05-31
PL327995A1 (en) 1999-01-04
CY2011011I1 (el) 2016-12-14
FR11C0035I2 (fr) 2013-08-16
CA2236691C (en) 2007-01-02
CZ140198A3 (cs) 1999-04-14
CN1206347A (zh) 1999-01-27
IL124551A (en) 2001-08-26
ID16927A (id) 1997-11-20
CY2011011I2 (el) 2016-12-14
BG102443A (en) 1999-06-30
HRP970276B1 (en) 2002-04-30
CN1093762C (zh) 2002-11-06
PT904081E (pt) 2002-04-29
MX9804816A (es) 1998-10-31
TW487572B (en) 2002-05-21
ES2167745T3 (es) 2002-05-16
EP0904081A1 (en) 1999-03-31
NO981984D0 (no) 1998-04-30
HU224025B1 (hu) 2005-05-30
DE122011100027I1 (de) 2011-11-17
SI0904081T1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
EE03594B1 (et) Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
EE03380B1 (et) Farmatseutiline aerosoolpreparaat ja selle valmistamismeetod
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
EE9900147A (et) Oksadiasoolid, nende saamismeetodid ja kasutamine ravimitena
HUP9900974A3 (en) Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
HUP0000426A3 (en) Novel benzonaphthyridines, pharmaceutical compositions and use thereof and process for their preparation
KR100547921B1 (ko) 설폰아미드-치환된크로만,이의제조방법및이를포함하는약제학적조성물
FI103704B1 (fi) Mikrobinvastainen koostumus, sen valmistusmenetelmä ja sen käyttö
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE9800200A (et) Bensoüülguanidiini derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE04119B1 (et) Külmkuivatamiseks sobiv ravimkoostis ja selle valmistamise meetod
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
AU2837089A (en) New indolylpiperidine compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
EE9900034A (et) Arüültsükloalkaankarboksüülestrid, nende kasutamine, farmatseutilised kompositsioonid ja valmistamine
EE03691B1 (et) 1,2,3,4-tetrahüdrobensofuro[3,4-c]püridiini derivaadid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
GB8917687D0 (en) Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
GB9123353D0 (en) New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
EE04260B1 (et) Farmatseutiline kompositsioon, selle valmistamisemeetod ja kasutamine
FI960316A (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE200100209A (et) Tritsüklilised 3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

AA1Y Spc filed

Free format text: PRODUCT NAME: XEPLION - PALIPERIDOON; REG NO/DATE: C(2011)1604 04.03.2011

Spc suppl protection certif: C20110009

Filing date: 20110725

FG1Y Spc granted

Free format text: PRODUCT NAME: XEPLION - PALIPERIDOON; REG NO/DATE: C(2011)1604 04.03.2011

Spc suppl protection certif: C20110009 00042

Filing date: 20110725

Extension date: 20220512